Evotec and Secarna Pharmaceuticals expand strategic partnership in the field of antisense drug discovery

  • Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG („Secarna“), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide („ASO“) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-secarna-pharmaceuticals-expand-strategic-partnership-in-the-field-of-antisense-drug-discovery-6094

    Du magst vielleicht auch